Phytochemicals against COVID-19 and a gap in clinical investigations: An outlook

Authors

  • VK Yadav 1Departmemnt of Botany, Banaras Hindu University, Varanasi-221 005, Uttar Pradesh, India
  • Prashant Kaushik 2 Instituto de Conservación y Mejora de la Agrodiversidad Valenciana, Universitat Politècnica de València-46022 Valencia, Spain

DOI:

https://doi.org/10.56042/ijbb.v58i5.44153

Keywords:

COVID-19, Pandemic, Phytochemicals, Trials

Abstract

The novel coronavirus 2019 (COVID-19) has presented an unexpected pandemic that has triggered severe panic among people worldwide. In this direction, nations are maximizing their efforts to battle the disease and lower illness. Plants that produce numerous bioactive compounds might help develop and keep immunity against chronic diseases and COVID-19. Medicinal plant-based treatments are trendy in rural and tribal communities, mainly as an outcome of the increased scalability, which causes them to be cheaper and affordable compared to present-day medication. Furthermore, additional research on the antiviral possibility of healing plants shown that plant extracts with incredibly energetic secondary metabolites are competent to interrupt the replication of numerous very pathogenic viruses. But the testing and clinical trials take a very long time. This review discusses the gap in clinical studies with available phytochemicals and the possible ways to cover the same.

Downloads

Published

2023-06-19

Issue

Section

Review

How to Cite

Phytochemicals against COVID-19 and a gap in clinical investigations: An outlook. (2023). Indian Journal of Biochemistry and Biophysics (IJBB), 58(5), 403-407. https://doi.org/10.56042/ijbb.v58i5.44153

Similar Articles

1-10 of 46

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)